3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
31
Phase 2
16
Phase 1/2
16
Phase 3
13
Phase NA
1
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
1
NIH
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Neoplasms
22
Breast Neoplasms
20
Neoplasm Metastasis
18
Colorectal Neoplasms
16
Stomach Neoplasms
15
Recurrence
15
Prostatic Neoplasms
15
Carcinoma, Hepatocellular
12
Pancreatic Neoplasms
11
Ovarian Neoplasms
11
Head and Neck Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
10
Lung Neoplasms
10
Leukemia, Myeloid, Acute
10
Myasthenia Gravis
9
Melanoma
9
Urinary Bladder Neoplasms
8
Lymphoma, Large B-Cell, Diffuse
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Liver Neoplasms
6
Cholangiocarcinoma
6
Carcinoma, Transitional Cell
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Lymphoma, Follicular
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia
5
Interventions
vocimagene amiretrorepvec
1
Temozolomide
1
Lomustine
1
Flucytosine
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
INDUSTRY
×
Astrocytoma
×
Clear all
NCT02414165
2020-02-07
Toca5
Tocagen Inc.
Phase 2/3
Terminated
403 enrolled